Exelixis Sues Cipla to Block Cabometyx Copies Till at Least 2030

Exelixis Inc. expanded its bid to protect Cabometyx, alleging in a new suit that a copy of the blockbuster cancer drug proposed by Cipla Ltd. infringes five patents, including three that are part of a clash with another generic-drug maker set for an October trial.

Those three patents expire in January 2030. They cover salt and polymorphic forms of Cabometyx’s active ingredient, cabozantinib; formulations of cabozantinib; and methods of treating cancer, including cancer of the kidney and liver.

Of the Cipla case’s other two patents, one expires in October 2030, and one in February 2032, according to a complaint filed ...